Marina Biotech, Inc. (OTCMKTS:MRNA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
Marina Biotech, Inc. (the Company) was held on May 16, 2017. As
of March 23, 2017, the record date for the Annual Meeting,
97,187,131 shares of common stock were issued and outstanding.
The holders of the Companys Series C Convertible Preferred Stock
(the Series C Stock) and the Companys Series D Convertible
Preferred Stock (the Series D Stock) were entitled to vote an
additional 7,550,000 shares at the Annual Meeting, on an
as-converted basis, without taking into account the beneficial
ownership limitations set forth in the Certificate of Designation
of Rights, Preferences and Privileges of each of the Series C
Stock and the Series D Stock. A summary of the matters voted upon
by stockholders at the Annual Meeting is set forth below. The
voting results reported below are final.
PROPOSAL No. 1
The Companys stockholders elected each of the Companys five (5)
director nominees listed below, each to serve as directors of the
Company until the 2017 Annual Meeting of Stockholders, based upon
the following votes:
| Nominee | Votes FOR | Votes WITHHELD | Broker Non-Votes | |||||||||
| Vuong Trieu, Ph.D. | 69,129,418 | 264,390 | -0- | |||||||||
| Philippe P. Calais, Ph.D. | 69,148,715 | 245,093 | -0- | |||||||||
| Stefan Loren, Ph.D. | 69,146,431 | 247,377 | -0- | |||||||||
| Philip C. Ranker | 69,138,722 | 255,086 | -0- | |||||||||
| Donald A. Williams | 69,149,244 | 244,564 | -0- | |||||||||
PROPOSAL No. 2
The Companys stockholders approved an amendment to the Companys
amended and restated certificate of incorporation to effect a
reverse stock split, at any time within two (2) years following
the Annual Meeting, and in such ratio between a one-for-two and
one-for-ten reverse stock split, to be determined by the Board of
Directors, to be in the best interest of the Company, based upon
the following votes:
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | ||||||||||
| 68,827,282 | 530,763 | 35,763 | -0- | ||||||||||
PROPOSAL No. 3
The Companys stockholders approved an amendment to the 2014 Long
Term Incentive Plan of the Company to increase the number of
shares available for issuance thereunder from 5,000,000 to
10,000,000, based upon the following votes:
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | ||||||||||
| 68,401,393 | 680,761 | 311,654 | -0- | ||||||||||
PROPOSAL No. 4
The Companys stockholders ratified the appointment by the Company
of Squar Milner LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017
based upon the following votes:
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | ||||||||||
| 69,177,681 | 184,505 | 31,622 | -0- | ||||||||||
PROPOSAL No. 5
The Companys stockholders approved, in a non-binding advisory
vote, the compensation of the Companys named executive officers,
based upon the following votes:
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | ||||||||||
| 68,915,137 | 354,154 | 124,517 | -0- | ||||||||||
About Marina Biotech, Inc. (OTCMKTS:MRNA)
Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2). Marina Biotech, Inc. (OTCMKTS:MRNA) Recent Trading Information
Marina Biotech, Inc. (OTCMKTS:MRNA) closed its last trading session 00.000 at 0.330 with 57,714 shares trading hands.